Nektar Therapeutics (NKTR)
36.25
-1.47
(-3.90%)
USD |
NASDAQ |
Oct 16, 11:21
Nektar Therapeutics SG&A Expense (TTM) : 53.46M for June 30, 2026
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 53.46M |
| March 31, 2026 | 57.77M |
| December 31, 2025 | 68.67M |
| September 30, 2025 | 74.62M |
| June 30, 2025 | 77.51M |
| March 31, 2025 | 80.95M |
| December 31, 2024 | 76.75M |
| September 30, 2024 | 76.94M |
| June 30, 2024 | 79.13M |
| March 31, 2024 | 76.48M |
| December 31, 2023 | 77.42M |
| September 30, 2023 | 82.04M |
| June 30, 2023 | 83.42M |
| March 31, 2023 | 86.08M |
| December 31, 2022 | 92.33M |
| September 30, 2022 | 102.54M |
| June 30, 2022 | 109.47M |
| March 31, 2022 | 118.50M |
| December 31, 2021 | 122.84M |
| September 30, 2021 | 117.84M |
| June 30, 2021 | 115.35M |
| March 31, 2021 | 110.14M |
| December 31, 2020 | 104.68M |
| September 30, 2020 | 104.69M |
| June 30, 2020 | 101.69M |
| Date | Value |
|---|---|
| March 31, 2020 | 99.92M |
| December 31, 2019 | 98.71M |
| September 30, 2019 | 95.35M |
| June 30, 2019 | 90.08M |
| March 31, 2019 | 87.76M |
| December 31, 2018 | 81.44M |
| September 30, 2018 | 70.00M |
| June 30, 2018 | 63.34M |
| March 31, 2018 | 59.08M |
| December 31, 2017 | 52.36M |
| September 30, 2017 | 52.79M |
| June 30, 2017 | 50.98M |
| March 31, 2017 | 46.02M |
| December 31, 2016 | 44.28M |
| September 30, 2016 | 44.75M |
| June 30, 2016 | 44.04M |
| March 31, 2016 | 43.19M |
| December 31, 2015 | 43.27M |
| September 30, 2015 | 42.28M |
| June 30, 2015 | 41.86M |
| March 31, 2015 | 41.30M |
| December 31, 2014 | 40.92M |
| September 30, 2014 | 38.51M |
| June 30, 2014 | 40.02M |
| March 31, 2014 | 39.63M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Eli Lilly & Co. | 12.24B |
| Inovio Pharmaceuticals, Inc. | 30.77M |
| Tonix Pharmaceuticals Holding Corp. | 125.96M |
| Capricor Therapeutics, Inc. | 35.43M |
| Kyntra Bio, Inc. | 27.67M |